Research and Markets (http://www.researchandmarkets.com/research/v8dx35/global)
has announced the addition of the "Global
Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J,
Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating"
report to their offering.
One of the main drivers is the increasing global aging population. Aged
patients have a greater number of dermatological disorders caused by
thinning and loss of elasticity of the epidermis.
Biologics are manufactured proteins interfering with the immune process
involved in any dermatological disorders. In recent years, the enhanced
understanding of the molecular basis underlying dermatological ailment
led to the introduction of biological drugs, providing a new effective
treatment option for dermatological disorders.
Biologics emphasizes on specific aspects of the immune function that
result in any illness. Along with topical treatments, the current market
is crowded with biologcs for dermatology. Amgen/Wyeth's Enbrel
continues to hold its position as market leader amongst biologics;
however, Abbott's Humira has increased its share significantly in the
past year. The pipeline is also very promising with biologics and
several other treatments for mild to moderate conditions. Hence, the
Global Dermatological Drugs market is expected to reap large revenues
with the increasing use of biologics.
Further, the report states that one of the key challenges is the risk of
side effects associated with dermatology drugs, which hampers the
acceptance of advanced biologic drugs for the treatment of dermatology
Key vendors dominating this space include
Other vendors mentioned in the report are
Key questions answered in this report:
For more information visit http://www.researchandmarkets.com/research/v8dx35/global
[ Back To NFVZone's Homepage ]